Clinical Trials

Below is a list of early phase clinical trials that may recruit from many different cancer diseases. To find out more about a particular clinical trial, click on the “study Information link” for the trial. Once you are in the study specific page, there is a link to contact the study team.

 

Early Phase/Multi Tumor Trials

 

  • STUDY17022

    First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Study Information


  • STUDY17262

    Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial

    Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.

    Study Information


  • STUDY17322

    A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

    The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114.

    Study Information


  • STUDY19304

    A Phase 1b/2 Study of HCW9218, a Bifunctional TGF ß Antagonist/IL 15 Protein Complex, for Advanced Pancreatic Cancer

    Evaluate the safety profile (as outlined by incidence of adverse events (AEs) based on CTCAE v5) of HCW9218 monotherapy in subjects with advanced/metastatic pancreatic cancer who have progressed on or are intolerant of standard first-line therapy. Determine the maximum tolerated dose (MTD) and designate the recommended Phase 2 dose level (RP2D) for Phase 2 study of HCW9218 in HCW9218-treated subjects. Evaluate the safety profile of HCW9218 in treated subjects. Determine the 6-month progression-free survival (PFS) rate of evaluable subjects treated with HCW9218.

    Study Information


  • STUDY21361

    A Phase 1/2 Open label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

    This study will assess the safety and tolerability of multiple dose levels of PC14586 in participants with advanced solid tumors containing a p53 Y220C mutation.

    Study Information